Aug 2026· Cell Transplantation· Vol 35· 0 citations· 18 references
Medicine
TL;DR
It is argued that pRBC xenotransfusion requires a purpose-specific translational framework rather than reliance on a single preclinical model, and such a framework should integrate standardized compatibility testing, in vitro human assays, animal-based safety stress-testing, and, where ethically and legally feasible, short-term human reference models.
Abstract
Genetically engineered porcine red blood cells (pRBCs) are emerging as a potential supplementary source of oxygen-carrying cells for transfusion medicine. Triple-knockout (TKO) pigs lacking major carbohydrate xenoantigens, including Gal, Neu5Gc, and Sd(a), have substantially reduced human antibody binding in vitro, and additional expression of human protective molecules such as CD55 and CD47 may further improve compatibility. However, the translational development of pRBC xenotransfusion is now constrained less by donor engineering alone than by the absence of an appropriate in vivo evaluation model. Old World nonhuman primates have historically served as essential preclinical models in xenotransplantation, but their cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH)-positive background and natural antibody repertoires may exaggerate immune barriers to TKO pRBCs that are not fully representative of humans. New World nonhuman primates, brain-dead human models, and eventually carefully regulated early-phase human studies each offer distinct advantages and limitations. In this Commentary, we argue that pRBC xenotransfusion requires a purpose-specific translational framework rather than reliance on a single preclinical model. Such a framework should integrate standardized compatibility testing, in vitro human assays, animal-based safety stress-testing, and, where ethically and legally feasible, short-term human reference models.
It is argued that scientific progress requires diverse new gene combinations and, ultimately, organ-tailored donor pigs, and the rationale for integrative endothelial humanization is synthesized.
Jeong Ho Hwang· Clinical transplantation and...· 0 citations
Advanced heart failure affects over 6 million adults in the United States alone. Orthotopic heart transplantation remains the definitive treatment, with over 90% one-year survival and meaningful gains in functional status and quality of life. The therapy is, however, constrained by an intractable supply problem. For de...
A. Abdelrehim, D. Hurst, W. H. Gray et al.· Frontiers in Transplantation· 0 citations
This review proposes a standardized perioperative management protocol that is applicable to clinical xenotransplantation and addresses consumptive coagulopathy; targeted suppression of macrophage- and neutrophil-driven innate inflammatory cascades, alongside activation of xenoreactive natural killer cells.
Kyu-Hyun Han, J. Yang· Clinical transplantation and...· 0 citations
Introduction Critically low blood donation rates and recurrent shortages in the blood supply have become pressing challenges in transfusion medicine. Xenotransfusion using porcine red blood cells (pRBCs) represents a promising alternative; however, risks of immune rejection and infection necessitate the development of...
Tra My Tran, Hyeon Ho Lee, T. H. Hwang et al.· Frontiers in Bioengineering...· 0 citations
The success of lung xenotransplantation will depend not on isolated technological breakthroughs but on the systematic integration of genetic engineering, immune modulation, and translational infrastructure, offering new hope to patients with end-stage lung disease.
Yue-Lin Fang, Jia-Ni Gao, Minjue Shan et al.· The Innovation Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.